Social Media Ideas for Jnj:ca

Johnson & Johnson (JNJ) Presents at Deutsche Bank 2026 Healthcare Summit Transcript

Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

Johnson & Johnson trades at a higher valuation with growing sales, while Pfizer's dividend yield is near 6% as patents expire from 2026 through 2030.

Johnson & Johnson: 3 Key Takeaways for Long-Term Investors

MedTech growth stalled while pharma surged, leaving the company to bet on new product launches and a planned spin-off to restore momentum.

Welcome to JnJ

Welcome to JnJ Anonymous (not verified) Mon, 10/12/2026 - 07:11 field_thread_url https://cafepharma.com/boards/threads/welcome-to-jnj.705944/...

Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect

Don't underestimate this healthcare giant.

Welcome to JnJ

Welcome to JnJ Anonymous (not verified) Tue, 10/13/2026 - 07:11 field_thread_url https://cafepharma.com/boards/threads/welcome-to-jnj.705944/...

Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts

Better Dividend King to Buy and Hold: Johnson & Johnson or Kenvue?

One healthcare dividend payer carries legal risk, the other faces a buyout. Here's which one actually deserves your money.

Looking for a Dividend Stock That Can Weather a Downturn? Start With Johnson & Johnson.

Even in a recession, there's strong demand for J&J's myriad of pharmaceutical and healthcare products.

I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now

The company is firing on all cylinders.

Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit

Johnson & Johnson (NYSE: JNJ) will present at the Deutsche Bank 2026 Healthcare Summit on Thursday, September 17 th, 2026. Management will participate in a Fireside Chat at 12:...

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.

Johnson & Johnson May Offload Its Orthopedics Unit for $20 Billion -- and Investors Shouldn't Miss What That Could S...

Healthcare giant Johnson & Johnson is looking to become a more profitable and faster-growing business.

I Think Johnson & Johnson Is the Best Dividend Stock to Buy Right Now

Looking for a dividend stock you can sleep well owning? Here's why Johnson & Johnson could be the long-term healthcare anchor your portfolio needs.

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient N...

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks com...

Pfizer: Growth Portfolio And Cost Cuts Support A Buy Through The LOE Trough

2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)

These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?

Should You Invest in This Dividend King on the Dip?

Looking beyond near-term headwinds paints a fairly bright picture of Johnson & Johnson’s outlook.

J&J orthopedics unit draws Apollo interest in potential $20 billion deal, Bloomberg News reports

GSK: Still One Of My Top Healthcare Picks

Divest BWI Now

Divest BWI Now Anonymous (not verified) Wed, 10/21/2026 - 13:15 field_thread_url https://cafepharma.com/boards/threads/divest-bwi-now.717817/...

Majestic Gold declares CAD 0.0055 special cash dividend

Philip Morris International Inc. 2026 Q3 - Results - Earnings Call Presentation

J&J earnings set ‘negative tone’; Shkreli vs. the FTC

A 6% sell-off in J&J shares was viewed by one analyst as emblematic of broader market volatility. Elsewhere, Gilead is collaborating with Vir and a biotech’s bid for a product...